Name a significant risk factor for increased bleeding in patients on antiplatelet therapy.

Age, particularly in older adults, is a significant risk factor for increased bleeding in patients on antiplatelet therapy due to several physiological changes that occur with aging. As individuals get older, there is often a decrease in renal function and changes in liver metabolism, which can affect the pharmacokinetics of antiplatelet agents. Additionally, older adults may have a higher prevalence of comorbid conditions, such as hypertension or diabetes, which can complicate their clinical status and increase their bleeding risk.

Moreover, older patients more frequently take multiple medications, raising the potential for drug interactions that may further enhance the effects of antiplatelet drugs. The presence of age-related vascular fragility can also make it easier for minor injuries to result in significant bleeding, amplifying the concern when these patients are on antiplatelet therapy.

In contrast, smoking or engaging in regular exercise doesn't have the same direct correlation with bleeding risk in the context of antiplatelet use. While smoking can have negative cardiovascular implications, it is not as directly linked to the mechanisms that affect bleeding risk. A high-fiber diet is generally associated with positive health outcomes and does not contribute to increased bleeding complications. Hence, age remains a key concern when managing ant